1.	Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-009, NCT00481871
2.	Phase II Study of 10-Propargyl-10-Deazaaminopterin in Patients With Advanced Non-Small Cell Lung Cancer (Summary Last Modified 09/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-99053, NCI-H99-0045, NCT00004238
3.	Phase II Study of 10-Propargyl-10-Deazaaminopterin in Patients With Recurrent or Refractory Aggressive Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-02078, NCI-H02-0100, NCT00052442
4.	Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-008, 2006-002811-29, NCT00364923
5.	Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment Phase: Phase II Type: Treatment Status: Completed Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-012, 2007-004673-26, NCT00606502
6.	Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-011, 2007-004671-19, NCT00722553
7.	Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-015, NCT00998946
8.	Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-014, 2008-006425-14, NCT01118624
9.	Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: OSU-10018, NCI-2010-01225, NCT01129206
10.	Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-112, NCT01183065
11.	Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 19 and over Sponsor: NCI, Other Protocol IDs: 569-10, NCI-2011-00254, P30CA036727, NCT01336933
12.	Phase I Study of 10-Propargyl-10-Deazaaminopterin and Probenecid in Patients With Advanced Solid Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-01014, NCI-H01-0077, NCT00024245
13.	Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-010, NCT00554827
14.	Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-018, NCT01134341